United Capital Financial Advisers, LLC Horizon Therapeutics Public LTD CO Transaction History

United Capital Financial Advisers, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$62.39 - $113.8 $38,432 - $70,100	-616 Reduced 9.08%	6,169 $702,000
Q3 2022 Nov 14, 2022	SELL	$58.92 - $84.67 $516,492 - $742,217	-8,766 Reduced 56.37%	6,785 $420,000
Q2 2022 Aug 11, 2022	BUY	$79.4 - $116.36 $869,668 - $1.27 Million	10,953 Added 238.21%	15,551 $1.24 Million
Q1 2022 May 16, 2022	SELL	$86.42 - $109.81 $8,987 - $11,420	-104 Reduced 2.21%	4,598 $484,000
Q4 2021 Feb 14, 2022	BUY	$98.56 - $119.91 $18,430 - $22,423	187 Added 4.14%	4,702 $507,000

Q3 2021 Nov 15, 2021	SELL	$91.91 - $110.37 $8,823 - $10,595	-96 Reduced 2.08%	4,515 $495,000
Q2 2021 Aug 13, 2021	SELL	$86.24 - $95.92 $23,284 - $25,898	-270 Reduced 5.53%	4,611 $432,000
Q1 2021 May 14, 2021	SELL	$71.83 - $95.48 $13,575 - $18,045	-189 Reduced 3.73%	4,881 $449,000
Q4 2020 Feb 17, 2021	BUY	$67.0 - $84.39 $61,908 - $77,976	924 Added 22.29%	5,070 $371,000
Q3 2020 Nov 13, 2020	BUY	$55.23 - $79.93 $11,598 - $16,785	210 Added 5.34%	4,146 $322,000
Q2 2020 Aug 13, 2020	BUY	$30.2 - $56.98 $118,867 - $224,273	3,936 New	3,936 $219,000

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.